MINNEAPOLIS, June 28, 2011 /PRNewswire/ — Lutonix today
announced receiving approval from the US Food and Drug
Administration to begin enrollment in its LEVANT 2 IDE clinical
trial for the treatment of peripheral arterial disease (PAD), along
with receipt of CE Mark for its drug-coated balloon and ISO
certification. Lutonix is the first company to receive
approval from the FDA to initiate a drug-coated balloon trial.
The company also announced two new additions to its leadership
team. Shawn McCormick was named Chief Operating Officer and
will oversee manufacturing, R&D, finance and administration for
the company. Leslie Trigg was named Executive Vice President,
Marketing and Commercial Strategy and will oversee all
commercialization aspects of the business.
LEVANT 2 Trial Set to Begin
LEVANT 2 is a global, multicenter, randomized study evaluating
the safety and efficacy of the Moxy™ Drug Coated Balloon
compared to a standard angioplasty balloon for treating diseased
leg arteries above the knee. The trial is designed to support
an application to the US FDA for approval of the Moxy balloon.
Co-principal investigators for this international study are
Dr. Ken Rosenfield (Massachusetts General Hospital, Boston MA) and
Dr. Dierk Scheinert (University of Leipzig, Leipzig Germany).
The LEVANT 2 trial was preceded by LEVANT 1, a multi-center,
prospective randomized trial of 101 patients with PAD. In
this study, the Moxy balloon was compared to standard angioplasty.
Data presented during the 2010 Transcatheter Cardiovascular
Therapeutics meeting showed that the Moxy balloon had the ability
to safely and substantially inhibit restenosis.
“Finding a durable treatment for PAD has proven to be one our
most difficult clinical challenges,” said Dr. Rosenfield.
“PAD patients are in great need of better treatment options.
This trial is an important step forward